reported the potential application of immune checkpoints, especially the PD‐1/PD‐L1 pathway, in the treatment of IPF, suggesting the possibility of utilizing these pathways as new therapeutic directions. This evidence concerns the gene CD274 and idiopathic pulmonary fibrosis.